Compare Blackrock Inc (BLK) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Blackrock Inc vs Incyte Corporation — how do they compare? Blackrock Inc trades at $1,042.99 (market cap $159.89B), while Incyte Corporation trades at $112.62 (market cap $22.82B). The key difference: Blackrock Inc is far larger — about 7× Incyte Corporation's market cap, and Blackrock Inc pays a 2.22% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| BLK | INCY | |
|---|---|---|
Market Cap | $159.89B | $22.82B |
Volume | 641,547 | — |
Sector | Financials | Health |
52-Week High | $1.20K | $118.52 |
52-Week Low | $922.90 | $67.38 |
Enterprise Value | $161.71B | $18.85B |
Dividend Yield | 2.22% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BlackRock (BLK) trades at $1,031.56, down 0.44% on the day, with a bullish technical signal and strong analyst consensus. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 results anticipated. Revenue grew to $24.22 billion in 2025, though net income margin dipped to 22.93%. The company maintains robust profitability metrics, including a 24.4% net income margin and 11.95% ROE. Recent news highlights the launch of a new Nasdaq-100 ETF, IQQ, challenging Invesco's QQQ.
The outlook for BLK remains positive, driven by earnings momentum, strategic ETF expansion, and solid institutional support. Key risks include market volatility affecting asset management fees and competitive pressures in the ETF space. With 76% of analysts rating it a Buy and a consensus price target of $1,290, the stock presents a compelling opportunity for growth-oriented investors, though monitoring Q2 earnings and macroeconomic trends is essential.
Incyte (INCY) trades at $114.23, down 2.12% today, with a bullish technical signal supported by moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.81, and revenue growth continues with 2025 revenue at $5.14 billion. Recent developments include positive Phase 1/2 data for VGA039 and the acquisition of Vega Therapeutics, expanding its hematology portfolio.
Outlook remains positive with analyst consensus favoring a Buy rating and a $112.78 price target. Key opportunities include pipeline advancements and robust profitability margins, while risks involve regulatory hurdles and competitive pressures in the biopharmaceutical sector. Earnings growth and product approvals are critical catalysts for future performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Blackrock Inc
BlackRock, Inc. provides investment management services to institutional clients and to retail investors through various investment vehicles. The Company manages funds, as well as offers risk management services. BlackRock serves governments, companies, and foundations worldwide.
Read more on BLK →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
